Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma, Inc. Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzuma…
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) P…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma Prices $125 Mln Offering Of Shares And Pre-funded Warrants; Stock Down
(RTTNews) - Crescent Biopharma, Inc. (CBIO), a clinical-stage biotechnology company, announced the pricing of its underwritten public offering of 8.09 million shares at a price of $14.50 per share, together with pre-funded warrants to purc…
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma to Present at June Investor Conferences
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, t…
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts antici…
Crescent Biopharma to Present at May Investor Conferences
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, t…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma, Inc. Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients,…
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an…
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
Crescent Biopharma, Inc. CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anti…
Huge Insider Buying in MGM and Salesforce
JasonDoiy / Getty Images As the year begins to wind down, investors are looking to position themselves for 2026. In recent days, insiders, including beneficial owners, at Crescent Biopharma Inc. (NASDAQ: CBIO), MGM Resorts International (N…
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs
Crescent Biopharma (CBIO) and Japan's Sichuan Kelun-Biotech Biopharmaceutical said Thursday that the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergist…
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Crescent Biopharma, Inc. Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global…
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global markets and Greater China…
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaborationdesignedtoaccelerateandexpandthedevelopmentofsynergisticcombina…
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced…
Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio
Company Logo The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global…
Crescent Biopharma GAAP EPS of -$1.27 beats by $0.08
* Crescent Biopharma press release [https://seekingalpha.com/pr/20296481-crescent-biopharma-reports-third-quarter-2025-financial-results-and-recent-business] (CBIO [https://seekingalpha.com/symbol/CBIO]): Q3 GAAP EPS of -$1.27 beats by $0.…
Crescent Biopharma to Present at November Investor Conferences
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced…
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced…
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating
Investing.com - Jefferies initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and set a price target of $26.00. The stock, currently trading at $15.06, has shown strong momentum with a 9.21% return over the past we…
Crescent Biopharma reports Q2 results
* Crescent Biopharma, Inc. press release [https://seekingalpha.com/pr/20184465-crescent-biopharma-reports-second-quarter-2025-financial-results-and-recent-business] (NASDAQ:CBIO [https://seekingalpha.com/symbol/CBIO]): Q2 Net loss was $21.…
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in Oncology Drug Developm…
Crescent Biopharma appoints Jan Pinkas as chief scientific officer
WALTHAM, Mass. - Crescent Biopharma, Inc. (NASDAQ:CBIO), a clinical-stage biotechnology company with a market capitalization of $9.87 million and analyst price targets ranging from $22 to $28, has appointed Jan Pinkas, Ph.D., as chief scie…
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or th…
Catalyst Biosciences stock initiated with Buy rating at Stifel on cancer drug
Investing.com - Stifel initiated coverage on Catalyst Biosciences (NASDAQ:CBIO) with a Buy rating and a $28.00 price target on Tuesday. For a comprehensive analysis of CBIO’s Fair Value and detailed financial metrics, check out InvestingPr…
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (…